In small molecule drug discovery and development, quantitative characterization of protein-small molecule interactions is a critical component of target validation, lead compound screening, and structure-activity relationship (SAR) assessment. Biacore technology, based on the principle of surface plasmon resonance (SPR), enables label-free, real-time detection of molecular interactions.